Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

With a diverse drug portfolio and a robust pipeline of ... of therapies across multiple clinical areas including oncology, ...

The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside ...

The 51-year-old from Northamptonshire, in central England, was diagnosed with incurable cancer in 2015. After he stopped ...

New Delhi: Reviewing the Phase III clinical trial protocol of the GZ402671 (Venglustat) presented by the pharma major Sanofi, ...

The US Food and Drug Administration (FDA) has announced it has approved colon cancer drug ... Zaltrap, developed by Sanofi and Regeneron Pharmaceuticals, will compete with Roche Holding AG ...

Access to innovation is proving increasingly difficult for UK cancer patients. Unpicking the policy barriers is important for ...

VIR's HDV and HBV treatments remain Vir's primary value drivers, with upcoming catalysts in Q4 2024 and 2025. Find out why ...

New Delhi: The drug major Sanofi Healthcare has got approval from the Subject Expert Committee (SEC) functional under the ...

Kymera Therapeutics is pivoting focus from oncology to immunology, with plans to only develop cancer programs beyond phase 1 studies via partnerships. | Kymera Therapeutics is pivoting its focus from ...

Among Sanofi’s rare disease drugs, new rare blood disorder drug ... over year to €92 million due to generic competition. In Oncology, Sarclisa sales rose 23.7% year over year to €114 million ...